Related references
Note: Only part of the references are listed.Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists
Chen Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Cachexia: A new definition
William J. Evans et al.
CLINICAL NUTRITION (2008)
Novel approaches to the treatment of cachexia
Josep M. Argiles et al.
DRUG DISCOVERY TODAY (2008)
Predictors of survival in COPD:: More than just the FEV1
Bartolorne R. Celli et al.
RESPIRATORY MEDICINE (2008)
A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in Pomc null mice
Y. C. Loraine Tung et al.
ENDOCRINOLOGY (2006)
Energy homeostasis and cachexia in chronic kidney disease
Robert H. Mak et al.
PEDIATRIC NEPHROLOGY (2006)
Appetite and energy balance signals from adipocytes
Paul Trayhurn et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2006)
Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice
JR Nicholson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia
MA Joppa et al.
PEPTIDES (2005)
The use of melanocortin antagonists in cachexia of chronic disease
JM Scarlett et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist
S Markison et al.
ENDOCRINOLOGY (2005)
Therapy Insight: cancer anorexia-cachexia syndrome - when all you can eat is yourself
A Laviano et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones
RA Frost et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2005)
Therapy Insight: cancer anorexia-cachexia syndrome - when all you can eat is yourself
A Laviano et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Identification of 2-{2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluoro-phenyl}-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model
TJ Vos et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Cancer anorexia-cachexia syndrome: cytokines and neuropeptides
EJB Ramos et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2004)
Peripherally administered [Nle4,D-Phe7]-α-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice
N Hoggard et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2004)
Cachexia in liver cirrhosis
M Plauth et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2002)
The hypothalamus and the control of energy homeostasis Different circuits, different purposes
G Williams et al.
PHYSIOLOGY & BEHAVIOR (2001)
Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1
P Puigserver et al.
MOLECULAR CELL (2001)
Mouse feeding behavior: ethology, regulatory mechanisms and utility for mutant phenotyping
SC Heinrichs
BEHAVIOURAL BRAIN RESEARCH (2001)
Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals
CJ Small et al.
DIABETES (2001)
Share Paper
